Syngene provides a range of services in the areas of diagnostics as well as therapeutic and vaccine R&D.
Syngene has an excellent track record in expression and purification of protein reagents and antibodies from various expression systems – bacterial, mammalian, insect cells, and yeast. We make and ship more than 2000 proteins a year to our clients.
Syngene produces SARS-CoV-2 specific, primers and probes. We provide custom oligos defined by our customers, as well as those mentioned in protocols recommended by WHO, CDC and ICMR.
Syngene collaborates and provides technical assistance to vaccine manufacturers for their virosome technology-based COVID-19 vaccine development. As part of the collaboration, Syngene will run animal immunization studies to validate the specific immune response to potentially create antibodies.